Cost-effectiveness of venous thromboembolism prophylaxis in total hip and knee replacement surgery: the evolving application of health economic modelling over 20 years
- 8 September 2008
- journal article
- review article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 24 (10) , 2993-3006
- https://doi.org/10.1185/03007990802443255
Abstract
Objectives: In the last two decades, there has been considerable evolution of methods for cost-effectiveness modelling. Some of the first models were developed in the area of venous thromboembolism (VTE) prophylaxis. Hence, this area can serve as an important example to illustrate evolving standards. Our objectives are to document evolving methodology by describing VTE models, assess their critical strengths and weaknesses, and inform future advances for models in this therapeutic area. Research design and methods: A systematic review of economic models of primary VTE prevention following hip and knee replacement surgery was undertaken. Electronic searches of PubMed, EMBASE, the Cochrane library, and grey literature were conducted (1985–2006). Reference lists of included articles and reviews were examined for relevant studies. Results: Twenty-nine cost-effectiveness models were identified. Nineteen other cost-effectiveness analyses were excluded because they were not model-based; 16 were simple cost calculations and three were analyses of resource use data collected alongside clinical trials. The majority of models (24) were constructed as decision trees, frequently utilising previously published model structures, with some adaptation for new comparators, and/or addition of relevant events omitted by earlier models (e.g., bleeding due to prophylactic treatment). Later models have included Markov processes to model potential long-term consequences of VTE (recurrent VTE and post-thrombotic syndrome) over longer time horizons. Systematic identification of clinical evidence and more sophisticated analysis methods (e.g., Bayesian mixed-treatment comparisons and probabilistic sensitivity analyses) have recently been introduced. Conclusions: Model structures have evolved substantially in this highly studied therapeutic area, with improvements made to the model structure, the comprehensiveness of clinical evidence included, and the underlying calculation methodology.Keywords
This publication has 54 references indexed in Scilit:
- Fondaparinux Sodium Compared with Enoxaparin SodiumAmerican Journal of Cardiovascular Drugs, 2005
- Pharmacoeconomic Analysis of Bemiparin and Enoxaparin as Prophylaxis for Venous Thromboembolism in Total Knee Replacement SurgeryPharmacoEconomics, 2004
- A Cost-Effectiveness Analysis of Fondaparinux Sodium Compared with Enoxaparin Sodium as Prophylaxis Against Venous ThromboembolismPharmacoEconomics, 2004
- Risk Factors of Recurrent Venous Thromboembolism: The Role of Residual Vein ThrombosisPathophysiology of Haemostasis and Thrombosis, 2003
- Cost-effectiveness of fondaparinux vs. enoxaparin as venous thromboembolism prophylaxis in SwedenThe European Journal of Health Economics, 2003
- Economic Evaluation of Enoxaparin as Postdischarge Prophylaxis for Deep Vein Thrombosis (DVT) in Elective Hip SurgeryValue in Health, 2000
- Economic Evaluation of Desirudin vs Heparin in Deep Vein Thrombosis Prevention after Hip Replacement SurgeryPharmacoEconomics, 1998
- Cost Effectiveness of a Low-Molecular-Weight Heparin in Prolonged Prophylaxis Against Deep Vein Thrombosis After Total Hip ReplacementPharmacoEconomics, 1998
- Thromboprophylaxis with Low Molecular Weight Heparin after Major Orthopaedic Surgery is Cost EffectiveDrugs, 1996
- Postphlebitic syndrome after hip arthroplasty: 43 patients followed at least 5 yearsActa Orthopaedica, 1994